publications

Hirschowitz, J., Casper, R., Garver, D.L. and Chang, S.: Lithium response in good prognosis schizophrenia: Am. J. Psych 137:8, 916-920, 1980. Breier, A., Hitzeman, R.J., Hirschowitz, J. and Garver, D.L. Kinetic analysis of platelet monoamine oxidase in chronic schizophrenia. Life Sciences 28, 1947-1951, 1981. Edelstein, P., Schultz, J.R., Hirschowitz, J., Kanter, D.R. and Garver, D.L. Physostigmine and lithium response in the schizophrenias. Am. J. Psych. 138:8, 1078-1981, 1981. Hirschowitz, J., Zemlan, F.P. and Garver, D.L. Growth hormone and Li ratios predict success of lithium in the schizophrenias. In Biological Markers in Psychiatry & Neurology. Usdin, I. and Hanin, E., (Eds.), Pergamon Press, Oxford, 307-316, 1982. Garver, D.L., Hirschowitz, J. and Hitzemann, R.J. Li ratios, lithium response and the schizophrenias. In Biological Markers in Psychiatry & Neurology. Usdin, I. and Hanin, E., (Eds.), Pergamon Press, Oxford, 169-176, 1982. McLure, S.P., Hirschowitz, J., Ritchel, W. and Hanenson, I.B. The usefulness of desipramine blood level monitoring: A case report. J. Clin. Psychopharm. 2:1, 51-53, 1982. Hirschowitz, J., Zemlan, F.P. and Garver, D.L. Growth hormone and lithium ratios predict success of lithium therapy in the schizophrenias. Am. J. Psych. 139:5, 646-649, 1982. Ben-Arie, O., George, G.C.W. and Hirschowitz, J. Compulsory treatment of 50 alcoholic drunken drivers: a follow-up study. SA. Med. Journal 63, 241-243, 1983. Hirschowitz, J., Bennett, J.A., Zemlan, F.P. and Garver, D.L. Thioridazine effect on desipramine steady-state levels. J.Clin.Psychopharm. 3:6, 376-379, 1983. Mavroidis, M., Kanter, D.R., Hirschowitz, J., and Garver D.L. Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology 81:354-356, 1983. Hitzemann, R., Hirschowitz, J., Zemlan, F., Hitzemann, B. and Garver, D.L. On the relation between platelet monoamine oxidase activity and growth hormone response in psychosis. Biological Psychiatry 18:12, 1503-1507, 1983. Hirschowitz, J. ECT: Guest Editorial. Focus on 5:1, 4, 1984. Zemlan, F.P., Hirschowitz, J., Sautter, F.J. and Garver, D.L. Impact of Li therapy on core psychotic symptoms of schizophrenia. Brit. J. Psych., 144:64-69, 1984. Bennett, J.A., Hirschowitz, J., Thurman, D.N. and Garver, D.L. Combined thioridazine and desipramine: Early antidepressant response. Psychopharmacology 82:263-265, 1984. Mavroidis, M.L., Kanter, D.R., Hirschowitz, J. and Garver, D.L. Therapeutic blood levels of Fluphenazine: Plasma or RBC determinations. Psychopharm. Bull. 20:1, 168-170, 1984. Garver, D.L., Hitzemann, R.J. and Hirschowitz, J. Li ratio in vitro. Arch. Gen. Psych., 41:5, 497-505, 1984. Garver, D.L., Hirschowitz, J., Fleischmann, R. and Djuric, P.E. Lithium response and psychosis: A double-blind placebo controlled study. Psychiatry Research. 12:57-68, 1984. Hitzemann, R.J., Sautter, F., Hitzemann, B., Hirschowitz, J. and Garver, D.L. Platelet monoamine oxidase activity in the psychoses: Relationship to symptoms and lithium response. Psychiatry Research, 11:221-222, 1984. Hitzemann, R.J., Hirschowitz, J., Hitzemann, B. and Garver, D.L. The prolactin response in schizophrenic, schizophreniform and manic disorders. Biological Psychiatry 19:6, 913-918, 1984. Zemlan, F.P., Hirschowitz, J. and Garver, D.L. Mood incongruent versus mood congruent psychosis: Differential antipsychotic response to lithium therapy. Psychiatry Research, 11:317-328, 1984. Mavroidis, M.L., Kanter, D.R., Hirschowitz, J. and Garver, D.L. Clinical relevance of thiothixene plasma levels. J. Clin. Psychopharmacology. 4:3, 155-157, 1984. Garver, D.L., Hirschowitz, J., Glickstein, G.A., Kanter, D.R. and Mavroidis, M.L. Haloperidol plasma and RBC levels and clinical response. J. Clin. Psychopharm. 4:3, 133-137, 1984. Garver, D.L., Hitzemann, R.J. and Hirschowitz, J. Lithium transport and the psychoses. In Psychiatry: The State of an Art. P. Berner (Ed.) Plenum Press, London, Vol. 3, 397-404, 1984. Hirschowitz, J., Zemlan, F.P., Hitzemann, R.J. and Garver, D.L. A biological test which distinguishes lithium responsive psychoses. In Psychiatry: The State of an Art. P. Berner (Ed.) Plenum Press, London, Vol. 3, 369-374, 1984. Garver, D.L., Hitzemann, R.J. and Hirschowitz, J. Lithium ratio and lithium response in the psychoses. In Psychiatry: The State of an Art. P. Berner (Ed.) Plenum Press, London, Vol. 3, 1984. Zemlan, F.P., Sautter, F.J., Hirschowitz, J. and Garver, D.L. Psychotic disorders responsive to lithium: Clinical features. In Psychiatry: The State of an Art. P. Berner (Ed.) Plenum Press, London, Vol. 3, 1984. Hitzemann, R.J., Hirschowitz, J. and Garver, D.L. Membrane methylation and lithium responsive psychoses. In Psychiatry: The State of an Art. P. Berner (Ed.) Plenum Press, London, Vol. 3, 405-410, 1984. Mavroidis, M.L., Kanter, D.R., Hirschowitz, J. and Garver, D.L. Fluphenazine plasma levels and clinical response. J. Clin. Psych. 45:370-373, 1984. Zemlan, F.P., Hirschowitz, J. and Garver, D.L. Lithium effects in schizophrenia (letters to the editor). Brit. J. Psychiatry. 145:91, 1984. Hitzemann, R.J., Hirschowitz, J. and Garver, D.L. Membrane abnormalities in the psychoses and affective disorders. J. Psychiatric Research. 18:3, 319-326, 1984. Garver, D.L., Zemlan, F., Hirschowitz, J., Hitzemann, R.J. and Mavroidis, M.L. Dopamine and non-dopamine psychoses Psychopharm. 84:138-140, 1984 Hitzemann, R.J., Hirschowitz, J., Panini, A., Mark, C. and Garver, D.L. Membranes, methylation and lithium responsive psychosis. Nutrition and Health. 3:153-162, 1984. Mavroidis, M.L., Garver, D.L., Kanter, D.R. and Hirschowitz, J. Plasma haloperidol levels and clinical response: confounding variables. Psychopharm. Bull. 21:1, 62-65, 1985. Hitzemann, R.J., Mark, C., Hirschowitz, J. and Garver, D.L. Characteristics of phospholipid methylation in human erythrocyte ghosts: relationships to the psychoses and affective disorders. Biol. Psychiatry, 20:397-407, 1985. Scharff, M.B., Hirschowitz, J., Woods, M. and Scharff, S. Lack of amnestic effects of clorazepate on geriatric recall. J. Clin. Psychiatry, 46:12, 518-520, 1985. Zemlan, F.P., Hitzemann, R.J., Hirschowitz, J. and Garver, D.L. Down regulation of dopamine receptors in schizophrenia. Am. J. Psych. 142:11, 1985. Scharff, M.B., Hirschowitz, J., Woods, M. and Lichstein, M. Comparative effects of limbitrol and amitriptyline on sleep efficiency and architecture. J. Clin. Pharmacol. 25:6, 1985. Scharff, M.B., Brown, D.C.J., Woods, M., Brown, L. and Hirschowitz, J. The effects and effectiveness of gamma hydroxybutrate in patients with narcolepsy. J. Clin. Psych. 46:6, 222-225, 1985. Mavroidis, M.L., Kanter, M.S., Hirschowitz, J. and Garver, D.L. Clinical relevance of neuroleptic plasma levels. J. Clin. Psych. 1985. Hirschowitz, J., Zemlan, F.P., Hitzemann, R.J., Fleischmann, R.L. and Garver, D.L. Growth hormone response to apomorphine and diagnosis: a comparison of three diagnostic systems. Biological Psychiatry. 21:445-454, 1986. Zemlan, F.P., Hirschowitz, J. and Garver, D.L. Relation of clinical symptoms to apomorphine stimulated growth hormone release in mood incongruent psychotic patients. Archives Gen. Psychiat. 43:1162-1167, 1986. Scharff, M.B., Brown, L. and Hirschowitz, J. Possible efficacy of alprazolam in restless leg syndrome. Hillside Journal of Clinical Psychiat. 8:2, 214-223, 1986. Zemlan, F.P., Hirschowitz, J., Sautter, F. and Garver, D.L. Clinical symptoms and brain pathology: traditional subtypes of schizophrenia may reflect unique brain abnormalities. Psychiat. Research 18:239-255, 1986. Hitzemann, R.J., Hirschowitz, J. and Garver, D.L. On the physical properties of red cell ghost membranes in the affective disorders and psychoses: a fluorescence polarization study. J. of Affective Disorders, 10, 227-232, 1986. Hitzemann, R.J., Garver, D.L., Mavroidis, M., Hirschowitz, J. and Zemlan, F.P. Fluphenazine activity and antipsychotic response. Psychopharmacology. 90:270, 1986. Scharff, M.B., Kauffman, R., Brown, L., Segal, J.J.and Hirschowitz, J. Morning amnestic effects of triazolam. Hillside Journal of Clinical Psychiatry, 8:1, 38-45, 1986. Zemlan, F.P., Hirschowitz, J., Sautter, F. and Garver, D.L. Relation of psychotic symptom clusters in schizophrenia to neuroleptic treatment and growth hormone response to apomorphine. Psychiatry Research, 18:239-255, 1986. Scharff, M.B., Hirschowitz, J., Zemlan, F.P., Lichstein, M.L. and Woods, M. Comparative effects of limbitrol and amitriptyline on sleep efficiency and architecture. J. Clin. Psychiat. 47:587-597, 1986. Sautter, F., Zemlan, F.P., Hirschowitz, J. and Garver, D.L. Growth hormone response to apomorphine and family patterns of illness. Biol. Psychiat. 22:717-724, 1987. Hitzemann, R.J., Kao, L., Hirschowitz, J., Garver, D.L. and Gruenstein, E. Lithium transport in human fibroblasts: relationships to RBC lithium transport and psychiatric diagnosis. Psychiatry Research, 24:337-344, 1988. Garver, D.L., Kelly, K., Fried, K.A., Magnussen, M. and Hirschowitz, J. Drug response as a basis of nosology for the mood incongruent psychoses (the schizophrenias). Psychological Medicine, 18:873-885, 1988. Aronson, T.A., Shukla, S. and Hirschowitz, J. Clonazepam prophylaxis in Lithium refractory patients with bipolar disorder. Am. J. Psychiat. 146:77-80, 1989 Hirschowitz, J., Hitzemann, R.J., Kovasznay, B., LaGrone, H., Folkerts, K., deRuyter, J., Teitelbaum, L., Dains, K., Hitzemann, B., and Mahajan, S. Lithium antagonism of ethanol induced intoxication: relationship to intracellular Lithium level. J. Psychiat. Research. 29:55-63, 1989. Hitzemann, R., Mark, C., Hirschowitz, J. and Garver, D.: RBC Lithium Transport in the Psychoses. Biological Psychiatry 25:296-304, 1989. Choc, M.G., Hsuan, F., Honigfeld, G., Robinson, W.T., Ereshesky, L., Crimson, L., Hirschowitz, J. and Wagner, R.: Single versus multiple dose Pharmacokinetics of Clozapine in Psychiatric patients. Pharmaceutical Research 7:4. 347-351, 1990. Volkow, N.D., Hitzemann, R.J., Wolf, A.P., Logan, J., Fowler, J.S., Christman, D., Dewy, S.L., Schlyer, D., Burr, G., Vitkun, S. and Hirschowitz, J. Acute Effects of Ethanol on Regional Brain Glucose Metabolism and Transport. Psychiatry Research: Neuroimaging. 35:39-48, 1990. Guggenheim, F.G.(editor), with Hirschowitz, J., Tsuang, M., Carson, K. and Moos, R. Psychiatric Research in VA: A 1989 Sampler. VA Practitioner. 7:1, 55, 1990. Hirschowitz, J., Hitzemann, R., Burr, G. and Schwartz, A. A New Approach to Dose Reduction in Chronic Schizophrenia. Neuropsychopharmacology. 5:103-113, 1991 Handelsman, L., Aronson, M., Maurer, G., Weiner, J., Jacobson, J., Bernstein, D., Ness, R., Herman, S., Losonczy, M., Song, I.S., Holloway, K., Horvath, T., Donnelly, N., Hirschowitz, J. and Rowan, J.: Neuropsychological and Neurological Manifestations of HIV-1 Dementia in Drug Users. J. of Neuropsychiatry and Clin. Neurosciences. 4:21-28, 1992. Kahn, R.S., Davidson, M., Hirschowitz, J., Stern, R. and Davis, K.L. Nocturnal Growth Hormone Secretion in Schizophrenic and Healthy Subjects. Psych. Research 41:151-166, 1992. Hirschowitz, J., Ayyala, M., Krishnamoorthy, G., Griffin, G. and Farrell, M.P. A Comparison of Hospital Charting Practices for Patients With Schizophrenia. H&CP 43:4, 392-393, 1992 Davidson, M., Kahn, R.S., Stern, R.G., Hirschowitz, J., Apter, S., Knott, P. and Davis, K.L. Treatment with Clozapine and its effects on Plasma Homovanilic Acid and Norepinephrine Concentrations in Schizophrenia. Psychiat. Research 46:151-163, 1993 Stern, R.G., Kahn, R.S., Davidson, M., Harvey, P.D., Amin, F., Apter, S.H. and Hirschowitz, J. Early Response to Haloperidol Treatment in Schizophrenia . Schiz. Research, 10: 165-171, 1993 Davidson, M. and Hirschowitz, J. Schizophrenia Research. Mt. Sinai J. Medicine 61, 5, 441-445, 1994. Stone, C.K. Garver, D. l., Griffith, J., Hirschowitz, J. and Bennett, J. Further Evidence of a Dose Response Threshold for Haloperidol and Psychosis. Am. J. Psychiat.152:8, 1210-1212, 1995 Schexnayder, L.W., Hirschowitz, J., Sautter, F.J. and Garver, D.L. Predictors of Response to Lithium in Patients with Psychoses. Am. J. Psych. 152:10, 1511-1513, 1995 Keefe, R.S.E., Fresca, E., Apter, S.H., Davidson, , M., Macaluso, J.M., Hirschowitz, J. and Davis, K.L.D. Clinical Characteristics of Kraepelinian Schizophrenia: Replication and Extension of Previous Findings. Am.J. psych. 153:6, 806-811, 1996 Harvey, P.D., Davidson, M., White, L., Keefe, R.S.E., Hirschowitz, J., Mohs, R.C. and Davis, K.L. Empirical Evaluation of the Factorial Structure of Clinical Symptoms in Schizophrenia: Effects of Typical Neuroleptics on the Brief Psychiatric Rating Scale. Biol. Psychiat.40:755-760, 1996 Vallabhajosula, S., Hirschowitz, J. and Machac, J. 123I-IBZM Brain Spect Imaging in Schizophrenics: Effect of Haloperidol Dose on the Uptake of the Tracer by the Basal Ganglia. J. Nucl. Med. 38:2, 203-207, 1997 Hirschowitz, J., Hitzemann, J., Piscani, K., Burr, G., Fresca, E., Culliton, D., Mann, M. and Curtis, C. The Dose Reduction in Schizophrenia (DORIS) Study: A final Report. Schizophrenia Research 23:1, 31-43, 1997 Hirschowitz, J. Hitzemann, R and Vallabhajosula, S. SPECT Studies of D2 Occupancy in Low Dose Haloperidol Treatment. Am. J. Psychiat. 54:5, 715-716, 1997 McQuistion, H.L., Finnerty, M., Hirschowitz, J. and Susser: E.S. Challenges for Psychiatry in Serving Homeless People with Mental Illness. Psychiatric Services 54: 669-676, 2003 Dunlop, B.W., Crits-Christoph, P., Evans, D., Solvason, Hirschowitz, J. and Ninan, P.T. Co-administration of Modafinal and an SSRI from the Initiation of Treatmtment for Major Depression with Fatigue and Sleepiness: A Double Blind Placebo Controlled Study. (In Review) Garakani, A., Hirschowitz, J. and Katz, C.L. General Disaster Psychiatry. Psychiatr. Clin. N. Am. 27, 391-406, 2004 Hitzemann, R., Burr, G., Piscani, K., Hazan, J., Krishnamoorthy, G., Cushman, P., Baldwin, C., Corrion, R., Volkow, N., Hirschowitz, J., Handelsman, L., Chiarmonte, J. and Angrist, B.: Neuroendocrine and Clinical Features of Cocaine Withdrawal. Psych. Research (in press) Stewart, D., Bartell, A., Barnett, D., Hirschowitz, J., Neugroschl, J., Wolberg, J., Katz, C., Aronson, A. and Marin, D: Rating Psychiatry Resident Applicants: Increasing Interrater Reliability Using the Resident Applicant Evaluation Scale (RAES) (in Review)
Garakani, A., Martinez, J., Marcus, S., Weaver, J., Rickels, K., Fava, M. and Hirschowitz, J. A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine Combined with Fluoxetine in Major Depressive Disorder. 2007, In Press Dunlop, B.W., Crits-Christoph, P., Evans, D.L., Hirschowitz, J., Solvason, B.H., Rickels, K., Garlow, S.J., Robert J. Galllup, R.J and Ninan, P. T. Co-administration of Modafinil and an SSRI from the Initiation of Treatment for Major Depressive Disorder with Fatigue and Sleepiness: A Double-Blind, Placebo-Controlled Study. J. of Clin. Psychopharmacology Volume 27, Issue 6 pages 614-619, December 2007 Published Abstracts
Hirschowitz, J., Casper, R., Garver, D.L. and Chang, S. Lithium response in good prognosis schizophrenia. Proc. Am. Psych. Assn., 132:349-340, 1979. Garver, D.L., Pandey, G.N., Hirschowitz, J. and Edelstein, P. Lithium ratio, schizophrenia and lithium response.Proc. Am. Psych. Assn. New Res., 132:26, 1979. Edelstein, P., Schultz, J.R., Hirschowitz, J. and Garver, D.L. Physostigmine and lithium response in schizophrenia. Proc. Am. Psych. Assn. New Res., 132:25, 1979. Hirsch, B., Lesinski, S.G., Hirschowitz, J. and Garver, D.L. Vestibular responses in schizophrenia. Proc. Am. Psych. Assn. New Res. 133:1, 1980. Hirschowitz, J. Li response in good prognosis schizophrenia. Psychiatric Topics, 1980. Hirschowitz, J., Garver, D.L., Galdi, J. Postsynaptic sensitivity, lithium and the schizophrenias. Proc. Am. Psych. Assn. 134:93, 233, 1981. Garver, D.L., Hirschowitz, J. and Klug, N. Biological and family studies in schizophrenia. J. Psych. Res. 15:132, 1981. Garver, D.L., Hirschowitz, J., Hitzemann, R.J. and Klug, N. Patterns of illness in Li responsive patients: illness course, biological markers and family history features. Proc. Am. Psych. Assn. 134:77, 159, 1981. Zemlan, F.P., Hirschowitz, J., Hitzemann, R.J. and Garver, D.L. Growth hormone, Li ratios and schizophrenia. Proc. Society Neuroscience, 7:441, 954, 1981. Hirschowitz, J., Garver, D.L., Zemlan, F.P. Growth hormone, Li and psychosis: a replication study. Proc. Am. Psych. Assn. 135:98, 276, 1982. Zemlan, F.P., Hirschowitz, J. and Garver, D.L. Early prediction of Li response in psychoses. Proc. Am. Psych. Assn. 135:97, 277, 1982. Zemlan, F.P., Hirschowitz, J. and Garver, D.L. Dopamine receptor supersensitivity predicts antipsychotic response to Li Co3 in a biologically distinct subgroup of psychotic patients. Neuroscience Abstracts, 8, 1982. Zemlan, F.P., Hirschowitz, J. and Garver, D.L. Prediction of Li responsiveness in schizophrenia. Clin. Psych. News 10:7, 15, 1982. Garver, D.L., Hirschowitz, J., Hitzemann, R.J. and Sautter, F.J. Lithium transport and the schizophrenias. Proc. Am. Psych. Assn. New Res. 135:72D, 180, 1982. Hitzemann, R.J., Garver, D.L. and Hirschowitz, J. Membrane methylation and lithium responsive psychoses. Proc. Am. Psych. Assn. New Res. 135:11, 1982. Mavroidis, M., Feldman, T.B., Hitzemann, R., Greenbaum, D.N., Hirschowitz, J., Kanter, D.R. and Garver, D.L. Clinical response and plasma neuroleptic levels in schizophrenia. Proc. Soc. Biol. Psych. 37:95, 126, 1982. Hirschowitz, J., Zemlan, F.P. and Garver, D.L. Dopamine receptor supersensitivity predicts antipsychotic response to Li2 Co3 in a biologically distinct subgroup of psychotic patients. Proc. Soc. Neurosci. 8:128, 1982. Hirschowitz, J., Bennett, J.A., Thurman, D.N. and Garver, D.L. Combined thioridazine and TCA: levels and response. Proc. Am. Psych. Assn. 136:117, 298, 1983. Zemlan, F.P., Garver, D.L. and Hirschowitz, J. Lithium effects psychosis not affective symptoms. Proc. Am. Psych. Assn. 136-NR 48, 1983. Garver, D.L., Mavroidis, M., Hitzemann, R.J. and Hirschowitz, J. Antipsychotic drug dose and blood level response patterns. Proc. Am. Psych. Assn. 136:61, 264, 1983. Hitzemann, R.J., Garver, D.L. and Hirschowitz, J. Cerebral spinal fluid metabolites and lithium responsive schizophrenia. Proc. Am. Psych. Assn. 136:NR 112, 1983. Garver, D.L., Hitzemann, R.J. and Hirschowitz, J. Lithium fluxes in schizophrenia. Proc. Am. Psych. Assn. 136:NR 113, 1983. Mavroidis, M.L., Kanter, D.L., Hirschowitz, J. and Garver, D.L. Therapeutic outcome and thiothixene plasma levels. VA Practitioner, 1:1, 78, 1984. Mavroidis, M.L., Kanter, D.R., Hirschowitz, J. and Garver, D.L. Clinical response and plasma haloperidol levels in schizophrenia. VA Practitioner, 1:1, 80, 1984. Hirschowitz, J., Bennett, J.A., Zemlan, F.P. and Garver, D.L. Thioridazine can boost desipramine levels. Currents in Affective Illness III: 1, 9, 1984. Garver, D.L., Zemlan, F.P., Hirschowitz, J. and Hitzemann, R.J. Dopamine and non-dopamine psychosis. Proc. Am. Psych. Assn. 137:NR 132, 1984. Zemlan, F.P., Hirschowitz, J., Hitzemann, R.J. and Garver, D.L. Dopamine functional subtypes of schizophrenia. Proc. Am. Psych. Assn. 137:NR 157, 1984. Garver, D.L., Hitzemann, R.J. and Hirschowitz, J. Diagnosis or Li ratio - which is the better predictor of Li response? Currents in Affective Illness III, 7, 4-5, 1984. Zemlan, F.P., Hirschowitz, J., Sautter, F.P. and Garver, D.L. Impact of Li therapy on core psychotic symptoms of schizophrenia. World Psychiatry, 2, 3, 1984. Hitzemann, R.J., Hirschowitz, J. and Garver, D.L. On the physical properties of red cell ghost membranes in the psychoses and affective disorders: a fluorescence polarization study. Soc. of Biol. Psychiat. 40:149, 1985. Bennett, J.A., Hirschowitz, J., Zemlan, F. and Garver, D.L. Effect of thioridazine on proposed desipramine therapeutic window. Proc. Am. Soc. of Hosp. Pharmacists. 88:87, 1985. Zemlan, F.P., Hirschowitz, J. and Garver, D.L. Dopamine receptor supersensitivity and psychosis. Proc. Am. Psych. Assn. 138:53, 172, 1985. Hirschowitz, J., Bennett, J.A., Zemlan, F. and Garver, D.L. Rapid dosing TCAD leads to early response. Proc. Am. Psych. Assoc. 138:NR 188, 1985. Garver, D.L., Hitzemann, R.J., Mavroidis, M.L. and Hirschowitz, J. Plasma antipsychotic sigmoidal response curves. Proc. Am. Psych. Assoc. 138:NR 6, 1985. Mavroidis, M.L., Kanter, D.R., Hirschowitz, J. and Garver, D.L. Clinical response and plasma haloperidol levels in schizophrenia. Year Book of Drug Therapy 1985. Garver, D.L., Mavroidis, M., Hitzemann, R.J. and Hirschowitz, J. Perspectives in antipsychotic blood levels and response. Proc. Psychiatric Research Soc. 26, 1985. Hitzemann, R.J., Garver, D.L., Hirschowitz, J., Zemlan, F.P. and Mavroidis, M.D. Plasma neuroleptic activity in schizophrenics. Proc. Am. Psych. Assn. 139:2, 200, 1986. Garver, D.L., Hitzemann, R.J., Zemlan, F.P., Hirschowitz, J. and Mavroidis, M.L. Neuroleptic activity and antipsychotic response. Proc. Am. Assn. 139:157, 261, 1986. Bennett, J.A., Hirschowitz, J., Zemlan, F. and Garver, D.L. Rapid dosing TCA leads to early response. Ohio Conference on Clinical Pharmacy and Clinical Pharmacology, 9:137, 1985. Hitzemann, R., Hirschowitz, J., and Garver, D.L. Neuroleptic dose adjustment by Dopamine Blockade. Proc. Am. Psych. Assn. l39:NR 246, l986. Zemlan, F.P., Hirschowitz, J., Sautter, F., Garver, D.L.Psychotic symptoms clusters and CNS pathology. Proc. Am. Psych. Assn. l39:ll9, 247, l986. Hirschowitz, J., Hitzemann, R.J., Kovasznay, B., LaGrone, H., Broggini, G. and Smith, R. Li and alcohol: Clinical and biological studies. Proc. Am. Psych. Assn. 140:NR57, 50, 1987. Hirschowitz, J., Hitzemann, R.J., Broggini, G. and Folkerts, K. Effect of Li on ethanol induced intoxication and plasma prolactin level. Neuroendocrinology letters. 9:3, 209, 1987. Baker, T., Hitzemann, R.J., Hirschowitz, J. and Gujavarty, K. Apomorphine stimulated growth hormone release in human narcolepsy. Proc. Society Neuroscience, 1987. Hirschowitz, J., Hitzemann, R., Hitzemann, B., Kovasznay, B., Broggini, G. and Folkerts, K. Plasma Haloperidol: GC vs. radioreceptor assay. Proc. Am. Psych. Assn. 141:NR97, 61, 1988. McDermott, B.E., Beasley, C., Kelly, K., Hirschowitz, J. and Garver, D.L. Confounds of Neuroscience Challenge Tests. Proc. Am. Psych. Assn. 141:NR98, 61, 1988. Choc, M.G., Hsuan, F., Honigfeld, G., Robinson, W.T., Ereshefsky, L., Hirschowitz, J. and Wagner, R.: Single vs. multiple dose pharmacokinetics of clozapine in Psychiatric patients. Proc.AAPS 1988. Hirschowitz, J., Hitzemann, R.J., Solomon, R.A., Gujavarty, K., Broggini, G., and Folkerts, K.: Neuroleptic dose adjustment by Dopamine blockade: Northport Biomedical Sciences Colloquium, 1988. Hirschowitz, J., Hitzemann, R.J., Hitzemann, B., Kovasznay, B., Brogini, G., and Folkerts, K.: Plasma Haloperidol: Gas chromatography vs. radioreceptor assay: Northport Biomedical Science Colloquium, 1988. Hitzemann, R.J., Hirschowitz, J., Broggini, G., Deacon, N., Dains, K., Folkerts, K., Futtersak, W., Solomon, R., and Mahajan, S. On the nature of Lithium-ethanol interactions. Northport Biomedical Sciences Colloqium, 1988. Errera, P., Greene, R., Tsuang, M., Carson, K., Moos, R., Hirschowitz, J., and Guggenheim, M.: Psychiatric Research: opportunities within the VA. Proc. Am. Psych. Assn., 142:W83, 347, 1989. Hirschowitz, J., Hitzemann, R.J., Burr, G. and Piscani, K. A new approach to dose reduction in the chronic patient. Proc.Am. coll.Neuropsychopharm. 28:117, 1989. Hirschowitz, J., Hitzemann, R.J., et al. A neuroendocrine method of dose reduction in schizophrenia. Proc.Am.Psych.Ass. 143:59, 89, 1990. Bromet, E., Schwartz, J., Rich, C., Ram, R., Lavelle, J., Geller, L., Kovasznay, B., Miller, A., Jandorf, L and Hirschowitz, J.:Suffolk County Mental Health Project: An Epidemiological Study of Newly Diagnosed Psychotic Patients.Proc.Am.Psychopath.Ass.1990. Hirschowitz, J., Hitzemann, R., Kahn, R., Piscani, C., Burr, G. and Mastroianni, L. D2 Receptor Blockade and Antipsychotic Response in Schizophrenia. Biol. Psych. 29:19, 51A, 1991. Kahn, R.S., Davidson, M., Hirschowitz, J., Stern, R.G., Davis, B.M., Gabriel, S., Moore, C. and Davis, K.L. Blunted Nocturnal Growth Hormone Secretion in Schizophrenic Patients. Proc. Am. Coll. Neuropsychopharm. 30:105, 1991. Garver, D.L., Bennett, J.A. and Hirschowitz, J. Delayed Responding Psychoses: Drug Level Response Relationships. Proc. Am. Coll. Neuropsychopharm. 30:175, 1991. Hirschowitz, J., Lobel, D., Aryan, A., Apter, S., Mohs, R. and Davis, K.L. Schiz. Subtypes: Temporal Stability. Proc. Am. Psychopath.Ass., 1992. Stone, J., Keefe, R. and Hirschowitz, J. Reliability of Schizophrenia Symptom Assessment. Proc. Am. Psych. Ass. 145:NR468, 162, 1992. Hirschowitz, J., Lobel, D., Arayan, M., Apter, S., Mohs, R. and Davis, K.l. Schiz. Subtypes: Stability Over Time. Proc. Am. Psych. Ass. 145: NR439, 155, 1992. Webster, L., Kahn, R.S., Davidson, M., Hirschowitz, J., Moore, C. and Davis, K.L. Nocturnal Growth Hormone Secretion in Schizophrenic Patients and Healthy Subjects. Biological Psychiatry 31:345, 210A, 1992. Kahn, R.S., Davidson, M., Hirschowitz, J., Stern R. G., Davis, B.M., Gabriel, S., Moore, C. and Davis, K.L. Nocturnal growth hormone secretion in schizophrenic patients and healthy subjects.Schizophrenia Research 6:2, 125, 1992. Stern, R. G., Kahn R.S., Davidson, M., Harvey, P.D., Amin, F., Apter, S., Dumont, K., Hirschowitz, J. and Davis, K.L. Significant decrease in psychopathology within three days of haloperidol treatment in chronic schizophrenia. Schizophrenia Research 6:2, 109, 1992. Hirschowitz, J., , Burr, G., Piscani, K., Mann, M. and Hitzemann, R.J. Receptor Occupancy and Neuroleptic Response in Schizophrenia. Schizophrenia Research 9:2, 3, 259, 1993. Hirschowitz, J., Hitzemann, R.J., Kaminski, R., Mann, M., Piscani, K. and Culliton, D. D2 Receptor Occupancy and Optimum Antipsychotic Dosing. Pro. Am. Psych. Ass. 146:87E, 239, ` 1993. Hitzemann, R.J., Hirschowitz, J., Macaluso, J., Kahn, R., Piscani, K. and Mann, M. Dose Reduction in Schizophrenia (DORIS) Study: Prelim. Report. Proc. Am. Psych. Assoc. 146:NR218, 113, 1993 Hirschowitz, J., Ayyala, M., Krishnamoorthy, G., Griffin, G. and Farrel, M.P. A Comparison of Hospital Charting Practices for Patients with Schizophrenia. Psychiatry Digest 4:22, 1993. Keefe, R.S.E., Fresca, E., Davidson, M., Apter, S.H., Blum, C., Macaluso, J., Losonczy, M.F., Hirschowitz, J., Mohs, R.C. and Davis, K.L. Validity of Kraepelinian Subtype of Schizophrenia. Proc. ACNP, 32:14, 1993 Garver, D.L., Bennet, J. and Hirschowitz, J. Threshold Doses for Antipsychotic Drug Response: Haloperidol. Proc. ACNP, 32:88, 1993 Hirschowitz, J., et al. Predictors of Response to Neuroleptic Treatment in Schizophrenia. Neuropsychopharm. 10: S-196, 840S, 1994 Epstein, J.I., Kahn, R.S., Macaluso, J.M., Sevy, S., Hirschowitz, J. and Davidson, M. Dopamine Agonist Treatment in Schizophrenia. Schizophrenia Research, 11:2, 108, 1994. Hirschowitz, J.and Falk, K. The Volunteer Psychiatrist and the Homeless. Proc. Am.Psych. Ass., 147:31D, 86, 1994. Falk, K., Dixon, L., Hirschowitz, J. and Weiden, P. House Calls for the Homeless: A New Model of Care. Proc. Am. Psych. Ass., 147: IW52, 246, 1994. Sevy, S., Keefe, R.S., Hirschowitz, J., Parrella, M., White, L., Heisler, L and Davidson, M. Negative Symptom Changes During Neuroleptic Treatment. Proc. Am. Psych. Ass., 147: 6C, 52, 1994. Hirschowitz, J., Vallabhajosula, S., Intrator, J., Hitzemann, R., DaCosta, M. and Machac, J. Antipsychotic Drug Therapy in Schizophrenics: Studies of Receptor Occupancy. Biol. Psychiatry, 35:9, 274, 691, 1994. Apter, S.H., Keefe, R.S.E., Hirschowitz, J., Davidson, M., Macaluso, J.M., Amato, R. and Davis, K.l. Longitudinal Classification in Schizophrenia: The Relationship between Kraepelinian and Deficit Syndrome Subtypologies. Biol. Psychiatry , 35:9, 288, 695, 1994. Garver, D.L., Griffith, J. and Hirschowitz, J. Minimum Effective Dose of Haloperidol in Treatment of Psychoses. Biol. Psychiatry, 35:9, 189, 667, 1994. Vallabhajosula, S., Machac, J., Hirschowitz, J., Dacosta, M., Lee, H., Lipszyc, H. and Muzinic, M. I-123-IBZM Spect Studies of Dopamine Receptor Occupancy in Schizophrenics: Effect of Antipsychotic Drug Therapy. Soc. Nuclear Medicine, 35:74, 1994. Harvey, P.D., White, L., Hirschowitz, J., Keefe, R.S.E., Davidson, M., Mohs, R.C. and Davis, K.L. The Influence of Neuroleptics on the Structure of Symptoms in Schiz.. ACNP, 1994. Garver, D.L., Sautter, F., Hirschowitz, J., Steinberg, J. and Griffith, J. Heterogeneity of the Psychoses: 1. Dopamine psychosis. Biol. Psychiat. 37:317, 1995 Garver, D.L., Sautter, F., Knoll, J., Hirschowitz, J., Steinberg, J., Kumar, N.G. and Griffith, J. Heterogeneity of the Psychoses: II. Neuro-Degenerative Psychosis. Biol. Psychiat. 37:318, 1995 Curtis, C., Burr, G., Piscani, K., Holland, J. and Hirschowitz, J. A Neuroendocrine Method of Dose Reduction: Final Report. Proc. Am Psych. Assn. NR148:111, 1995 Hirschowitz, J. Hitzemann, R., Curtis, C. and Piscani, K. Dose reduction in Schizophrenia. Proc. Am. College of Neuropsychopharm. 34:166, 1995 Kingsbury, S.J., Thamilarisi, R.N., Hirschowitz, J., Mc Dermott, B.E. and Garver, D.L.Subtyping Psychoses: A Lithium Responsive non Affective Syndrome. ACNP.34:253, 1995 Hirschowitz, J., Fennig, S. and Bromet, E. Schizoaffectives vs Schiz and Affective: A follow up.Proc. Am. Psych. Assn. 95:37, 1996 Hirschowitz, J., Curtis, C., Hitzemann, R.J., Piscani, K. and Mann, M. Plasma Haloperidol in chronic Schiz: New Findings. Proc. Am.Psych. Assn. 14:7, 1996 Badgett, S., Hitzemann, R.J., Burr, G., Piscani, K., Fresca, E. and Hirschowitz, J. Dose Reduction in Schizophrenia. Proc. Am. Psych. Assn. NR560:222, 1996 Hirschowitz, J. Low Dose Treatment Studies in Schizophrenia. Proc. N. Y. State O. M. H. Research Conf. PS2:27, 1997 Fotiades, J., Bacon, S.J., Meyerson, L.J., Caparelli, I., Hirschowitz, J., Craig, T.and Siever, L. Improving The Screening, Diagnosis and Treatment of Major Depressive Disorder (MDD) in Primary Care. Proc. Clin. Practice Guidelines Conference, Department of Veterans Affairs, 1999 Stewart, D., Bartell, A., Barnett, D., Hirschowitz, J., Neugroschl, J., Wolberg, J., Katz, C., Aronson, A. and Marin, D: Rating Psychiatry Resident Applicants: Increasing Interrater Reliability Using the Resident Applicant Evaluation Scale (RAES). Proc.Am. Psych. Assn. 154 NR 2001 Hirschowitz, J. New York City and Disaster Psychiatry: 9\11 and Beyond. Proc. Japan Soc. Emerg. Psych. 10:13, 2002 ACNP workshop with Lynn Delisi Schlechter, A D., Roter, D., Brickman, A M., Edwards, E. and Hirschowitz, J. The Doctor-Patient Relationship, Medication Adherence, and Schizophrenia. Proc. Am. Psych. Assn. NR59, 2004 Schlechter, A.D., Brickman, A., Roter, D., Riggio, S. and Hirschowitz, J. Identifying Aspects of the Doctor-Patient Relationship that are Preferred by Patients with Schizophrenia. Proc. AAPP, 2004 Hirschowitz, J. and Stewart D. A Model Communications Course for Psychiatry Residents. Proc. AADPRT 34:3.03, 39, 2005 Hirschowitz, J. Advances in the Treatment of Bipolar Disorder: Unraveling the Evidence. Proc. AADPRT 35:2.12, 66, 2006